Crown Bioscience

Crown Bioscience, a JSR Life Sciences company and global CRO, specializes in oncology and immuno-oncology drug discovery and development.

[Crown Bioscience @crownbioscience]

With flexible licensing options for datasets spanning WES, RNA-Seq, proteomics and more, accessing OMICS and SoC datasets has never been easier.

Discover data licensing opportunities from our industry-leading PDX and organoid models: https://t.co/ecgz8LJI8A

[Crown Bioscience @crownbioscience]

We’re pleased to launch our Small Panel Bone Marrow Niche platform.

The Small Panel format reduces study conditions from 30+ to fewer than 15, helping researchers access a more flexible and resource-efficient approach for hematological cancer studies.

https://t.co/kAxMFy5q6E

[Crown Bioscience @crownbioscience]

Our unified approach to biomarker testing – spanning validated assays, high-quality biospecimens, and integrated data analysis – brings stronger insights, reduced risk, and more confident decision-making to your clinical biomarker strategy.
https://t.co/RoGU7NQNw5

[Crown Bioscience @crownbioscience]

Clinical biomarker strategies are essential for guiding drug development, but their complexity can delay insights and limit impact.

Discover how our integrated biomarker services support more informed clinical decisions: https://t.co/j1LLyrNsDX

[Crown Bioscience @crownbioscience]

PA20006B is a primary-site pancreatic organoid model derived from a patient sample.

Recapitulate key characteristics of parental tumors and support more informed evaluation of tumor biology and therapeutic response.

Explore PA20006B and more: https://t.co/3sG7SNVFu8

[Crown Bioscience @crownbioscience]

Looking for the best customer experience available in the industry? Explore our monthly Customer Satisfaction Report: https://t.co/EZqucYdS4s

[Crown Bioscience @crownbioscience]

Our AACR 2026 Poster demonstrates how organoid fibroblast co-culture systems, combined with high-content imaging (HCI), improve the assessment of tumor killing, immune infiltration and resistance mechanisms. https://t.co/ifCCNGrlv7

[Crown Bioscience @crownbioscience]

Crown Bioscience will be attending the 74th ASMS Conference on Mass Spectrometry and Allied Topics in San Diego.

Schedule a meeting: https://t.co/AkqTlNVzhQ

[Crown Bioscience @crownbioscience]

In this on-demand webinar, Rekha Pal, PhD, provides a masterclass in integrating pharmacokinetics (PK) with pharmacodynamics (PD) to transform raw data into a roadmap for candidate success.
Watch now: https://t.co/NlsKdEMge6

[Crown Bioscience @crownbioscience]

This study highlights how advanced organoid-based 3D in vitro platforms can improve the translational relevance of immunotherapy testing by more accurately modeling the tumor microenvironment.
https://t.co/ilVFBMigmB

[Crown Bioscience @crownbioscience]

Did you know skin cancer is the most common type of cancer in the US? ¹ This Skin Cancer Awareness Month, we’re highlighting research advancements in melanoma cancer treatment.
https://t.co/bmSRqGaWzQ
¹https://t.co/R68n1GIDpA

[Crown Bioscience @crownbioscience]

From target validation and biomarker discovery to hypothesis testing and AI/ML model development, Crown Bioscience Data Licensing empowers confident decision-making during oncology drug discovery.
Discover more: https://t.co/1tn1FljCil

[Crown Bioscience @crownbioscience]

Crown Bioscience’s Model of the Month, CR9831, is a colorectal cancer PDX derived from a heavily pretreated patient, featuring prior exposure to an anti-c-MET ADC (ABBV-400).

Partner with us to access models that mirror today’s clinical landscape.
https://t.co/Ioc7omavRR

[Crown Bioscience @crownbioscience]

Our unified approach to biomarker testing – spanning validated assays, high-quality biospecimens, and integrated data analysis – brings stronger insights, reduced risk, and more confident decision-making to your clinical biomarker strategy.

https://t.co/sV01bvrDv7

[Crown Bioscience @crownbioscience]

Join Crown Bioscience & Vilber for “Advancing Oncology Drug Development: From Resistance Mechanisms to Preclinical Innovation,” an afternoon of scientific discussion focused on overcoming resistance and accelerating oncology drug development.
Register now:
https://t.co/SVNmswLSs8

[Crown Bioscience @crownbioscience]

Crown Bioscience CEO John Gu talks about the need for different approaches among different cultures – with firsthand insights into how we achieve success across our multicultural teams.

Read the interview in full: https://t.co/DYPZNbFmpC

[Crown Bioscience @crownbioscience]

This World Ovarian Cancer Day, we’re highlighting the need to overcome resistance to existing treatments. Precision medicine & targeted therapies like PARPi¹ help improve patient outcomes but resistance to PARPi remains a challenge.https://t.co/m00KBB6WMY
¹https://t.co/bnP6vQTzEw

[Crown Bioscience @crownbioscience]

AACR may be over, but the science continues.
We’re sharing a closer look at four of our poster presentations, highlighting how we’re advancing translational research across some of today’s most complex therapeutic challenges.
https://t.co/urUMY3y89H

[Crown Bioscience @crownbioscience]

Listen in to our latest Smart Biotech Scientist Podcast episode, as Dr. David Brühlmann speaks with Bryan Miller about the importance of developing a robust strategy and why partnering with a CRO provides value.

Catch their insights in full: https://t.co/kuh4Sn8XwI

[Crown Bioscience @crownbioscience]

Advanced preclinical systems are helping researchers model complex CGT mechanisms with greater accuracy. Benjamin Wilkin explains why this will be essential for translating promising therapies into clinical success as the field continues to advance: https://t.co/L2f1eP5xEl